Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy

被引：70
|
作者：
Queirolo, Paola [1 ]
Boutros, Andrea [1 ]
Tanda, Enrica [1 ]
Spagnolo, Francesco [1 ]
Quaglino, Pietro [2 ]
机构：
[1] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy
[2] Univ Turin, Med Sch, Dept Med Sci, Dermatol Clin, Turin, Italy
来源：
SEMINARS IN CANCER BIOLOGY | 2019年 / 59卷
关键词：
Melanoma; Immunotherapy; Immune-checkpoint inhibitors; CTLA-4; PD-1; Biomarker; CUTANEOUS ADVERSE EVENTS; OPEN-LABEL; COMBINED NIVOLUMAB; TUMOR RESPONSE; CHECKMATE; 037; DOUBLE-BLIND; IPILIMUMAB; PEMBROLIZUMAB; SURVIVAL; PHASE-3;
D O I：
10.1016/j.semcancer.2019.08.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.
引用
收藏
页码：290 / 297
页数：8
相关论文
共 50 条
  • [21] Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
    Teresa Kim
    Rodabe NAmaria
    Christine Spencer
    Alexandre Reuben
    Zachary ACooper
    Jennifer AWargo
    Cancer Biology & Medicine, 2014, 11 (04) : 237 - 246+213
  • [22] Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
    Teresa Kim
    Rodabe N.Amaria
    Christine Spencer
    Alexandre Reuben
    Zachary A.Cooper
    Jennifer A.Wargo
    Cancer Biology & Medicine, 2014, (04) : 237 - 246
  • [23] Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa
    Ford, Joshua
    Thuro, Bradley A.
    Thakar, Sudip
    Hwu, Wen-Jen
    Richani, Karina
    Esmaeli, Bita
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 33 (04): : E82 - E85
  • [24] Immune checkpoint inhibitors in cancer immunotherapy
    Himmel, Megan E.
    Saibil, Samuel D.
    Saltman, Alexandra P.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (24) : E651 - E651
  • [25] Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma
    Koppolu, Veerendra
    Vasigala, Veneela Krishna Rekha
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1167 - 1175
  • [26] Palisaded neutrophilic granulomatous dermatitis in a patient with a history of metastatic melanoma previously treated with immune-checkpoint inhibitors
    Kranyak, A.
    Lee-Foltz, M. M.
    Salem, I.
    Hodson, E.
    Chapman, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S112 - S112
  • [27] The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
    Ghidini, Michele
    Fusco, Nicola
    Salati, Massimiliano
    Khakoo, Shelize
    Tomasello, Gianluca
    Petrelli, Fausto
    Trapani, Dario
    Petrillo, Angelica
    CURRENT DRUG TARGETS, 2021, 22 (09) : 1021 - 1033
  • [28] Immune checkpoint inhibitors for the treatment of melanoma
    Sabbatino, Francesco
    Liguori, Luigi
    Pepe, Stefano
    Ferrone, Soldano
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (05) : 563 - 576
  • [29] Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
    de Moel, Emma C.
    Rozeman, Elisa A.
    Kapiteijn, Ellen H.
    Verdegaal, Els M. E.
    Grummels, Annette
    Bakker, Jaap A.
    Huizinga, Tom W. J.
    Haanen, John B.
    Toes, Rene E. M.
    van der Woude, Diane
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) : 6 - 11
  • [30] Cardiotoxicity in cancer patients treated with immune-checkpoint inhibitors
    Franco, F. F.
    Garitaonaindia, Y.
    Blanco Clemente, M.
    Torrente, M.
    Calvo de Juan, V.
    Collazo Lorduy, A.
    Gutierrez, L.
    Sanchez, J. C.
    del Alba Baamonde, M. A. Gonzalez
    Royuela, A.
    Visedo, G.
    Gonzalez, S. C.
    Martinez Cutillas, M.
    Traseira Puchol, C.
    Aguado, R.
    Mitroi, C. D.
    Provencio, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1406 - S1406
12345